These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20963595)

  • 21. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction).
    Holmvang L; Kelbæk H; Kaltoft A; Thuesen L; Lassen JF; Clemmensen P; Kløvgaard L; Engstrøm T; Bøtker HE; Saunamäki K; Krusell LR; Jørgensen E; Tilsted HH; Christiansen EH; Ravkilde J; Køber L; Kofoed KF; Terkelsen CJ; Helqvist S
    JACC Cardiovasc Interv; 2013 Jun; 6(6):548-53. PubMed ID: 23683734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
    Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE; Martinez EE;
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):665-73. PubMed ID: 19670303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective randomized trial of everolimus-eluting stents versus bare-metal stents in octogenarians: the XIMA Trial (Xience or Vision Stents for the Management of Angina in the Elderly).
    de Belder A; de la Torre Hernandez JM; Lopez-Palop R; O'Kane P; Hernandez Hernandez F; Strange J; Gimeno F; Cotton J; Diaz Fernandez JF; Carrillo Saez P; Thomas M; Pinar E; Curzen N; Baz JA; Cooter N; Lozano I; Skipper N; Robinson D; Hildick-Smith D;
    J Am Coll Cardiol; 2014 Apr; 63(14):1371-5. PubMed ID: 24216285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial.
    Stella PR; Belkacemi A; Dubois C; Nathoe H; Dens J; Naber C; Adriaenssens T; van Belle E; Doevendans P; Agostoni P
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1138-46. PubMed ID: 22422607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
    Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
    Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcomes of elective drug-eluting stenting of the unprotected left main coronary artery in patients with normal left ventricular function.
    Lee MS; Yang T; Biondi-Zoccai G; Sillano D; Cerrato E; Tarantini G; Xhaxho J; Aragon J; Sheiban I
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):945-51. PubMed ID: 20824773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with drug-eluting stents in patients with myocardial infarction.
    Lee MS; Sillano D; Latib A; Chieffo A; Zoccai GB; Bhatia R; Sheiban I; Colombo A; Tobis J
    Catheter Cardiovasc Interv; 2009 Jan; 73(1):15-21. PubMed ID: 19089930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and effectiveness of drug eluting stent in patients with ST elevation myocardial infarction undergoing primary angioplasty.
    Romano M; Buffoli F; Tomasi L; Corrado L; Ferrari MR; Zanini R
    Catheter Cardiovasc Interv; 2008 May; 71(6):759-63. PubMed ID: 18412066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repeated sirolimus-eluting stent implantation to treat sirolimus-eluting stent and bare-metal stent restenosis.
    Nishihira K; Shibata Y; Ishikawa T; Nomura K; Nakama T; Mine D; Inoue Y; Ashikaga K; Kuriyama N; Matsuyama A; Imamura T; Asada Y; Kitamura K
    Circ J; 2010 Nov; 74(11):2329-33. PubMed ID: 20890050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug eluting stenting in bifurcation coronary lesions long-term results applying a systematic treatment strategy.
    Assali AR; Vaknin-Assa H; Lev E; Teplitsky I; Dvir D; Brosh D; Bental T; Battler A; Kornowski R
    Catheter Cardiovasc Interv; 2012 Mar; 79(4):615-22. PubMed ID: 22162218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early and long-term results of unprotected left main coronary artery stenting: the LE MANS (Left Main Coronary Artery Stenting) registry.
    Buszman PE; Buszman PP; Kiesz RS; Bochenek A; Trela B; Konkolewska M; Wallace-Bradley D; Wilczyński M; Banasiewicz-Szkróbka I; Peszek-Przybyla E; Krol M; Kondys M; Milewski K; Wiernek S; Debiński M; Zurakowski A; Martin JL; Tendera M
    J Am Coll Cardiol; 2009 Oct; 54(16):1500-11. PubMed ID: 19699048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis.
    Singh IM; Filby SJ; El Sakr F; Gorodeski EZ; Lincoff AM; Ellis SG; Shishehbor MH
    Catheter Cardiovasc Interv; 2010 Aug; 76(2):257-62. PubMed ID: 20665874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of unprotected left main disease with drug-eluting stents in patients at high risk for coronary artery bypass grafting.
    Barlis P; Horrigan M; Elis S; Chan R; Wong M; Farouque O; Proimos G; Ajani AE; Clark DJ
    Cardiovasc Revasc Med; 2007; 8(2):84-9. PubMed ID: 17574165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing long-term outcomes between drug-eluting and bare-metal stents in the treatment of cardiac allograft vasculopathy.
    Nfor T; Ansaarie I; Gupta A; Bajwa T; Allaqaband S
    Catheter Cardiovasc Interv; 2009 Oct; 74(4):543-9. PubMed ID: 19405161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective drug-eluting stent implantation for high-risk patients with acute ST-elevation myocardial infarction: rationale and safety.
    Prasad SB; David T; Malaiapan Y; Cameron JD; Meredith IT
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):193-200. PubMed ID: 20549694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
    Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group.
    Brodie BR; Stuckey T; Downey W; Humphrey A; Bradshaw B; Metzger C; Hermiller J; Krainin F; Juk S; Cheek B; Duffy P; Smith H; Edmunds J; Varanasi J; Simonton CA;
    JACC Cardiovasc Interv; 2008 Aug; 1(4):405-14. PubMed ID: 19463338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.
    Novack V; Cutlip D; Kleiman N; Pencina M; Mauri L; Yen CH; Berger P; Goldberg S; Kellett M; Waksman R; Hong M; Raizner AE; Cohen DJ
    JACC Cardiovasc Interv; 2009 Aug; 2(8):767-75. PubMed ID: 19695546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.